Frontier Capital Management Co. LLC Has $6.04 Million Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Frontier Capital Management Co. LLC cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 61.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 150,172 shares of the company’s stock after selling 242,091 shares during the period. Frontier Capital Management Co. LLC’s holdings in Kymera Therapeutics were worth $6,041,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in KYMR. Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics by 35.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock worth $1,356,000 after purchasing an additional 7,647 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after buying an additional 95,547 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after buying an additional 684 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. Finally, KBC Group NV increased its holdings in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Stephens reaffirmed an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, Citigroup assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $52.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last 90 days. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Down 2.3 %

KYMR stock opened at $30.07 on Friday. The firm has a 50-day moving average price of $29.57 and a 200-day moving average price of $37.67. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The stock has a market capitalization of $1.96 billion, a P/E ratio of -12.85 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company’s quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.69) earnings per share. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.